16Mar 2025
Hydrocortisone Does Not Alter PDA Impact in Preterm Infants

Hydrocortisone Does Not Alter PDA Impact in Preterm Infants

A post hoc analysis of the NICHD NRN HC trial found that hydrocortisone (HC) did not modify the relationship between patent ductus arteriosus (PDA) and adverse outcomes in extremely preterm infants. PDA was associated with increased ventilatory support, severe bronchopulmonary dysplasia (BPD), and lower weight-for-age Z-scores, regardless of HC treatment. These findings suggest that PDA independently contributes to poor neonatal outcomes.

  • #pediatrics

Like

Save

Share